Assertio (ASRT) Competitors $0.65 -0.01 (-1.49%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. CDTX, HUMA, DRUG, LFCR, ALMS, IMMP, CRVS, YMAB, FHTX, and PROKShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Cidara Therapeutics (CDTX), Humacyte (HUMA), Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), Alumis (ALMS), Immutep (IMMP), Corvus Pharmaceuticals (CRVS), Y-mAbs Therapeutics (YMAB), Foghorn Therapeutics (FHTX), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Cidara Therapeutics Humacyte Bright Minds Biosciences Lifecore Biomedical Alumis Immutep Corvus Pharmaceuticals Y-mAbs Therapeutics Foghorn Therapeutics ProKidney Assertio (NASDAQ:ASRT) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership. Which has better valuation & earnings, ASRT or CDTX? Cidara Therapeutics has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAssertio$124.96M0.50-$331.94M-$0.23-2.82Cidara Therapeutics$1.28M179.46-$22.93M-$30.09-0.69 Does the MarketBeat Community favor ASRT or CDTX? Cidara Therapeutics received 345 more outperform votes than Assertio when rated by MarketBeat users. Likewise, 70.31% of users gave Cidara Therapeutics an outperform vote while only 59.89% of users gave Assertio an outperform vote. CompanyUnderperformOutperformAssertioOutperform Votes11259.89% Underperform Votes7540.11% Cidara TherapeuticsOutperform Votes45770.31% Underperform Votes19329.69% Which has more volatility & risk, ASRT or CDTX? Assertio has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Do analysts recommend ASRT or CDTX? Assertio currently has a consensus price target of $2.75, suggesting a potential upside of 323.34%. Cidara Therapeutics has a consensus price target of $39.14, suggesting a potential upside of 87.38%. Given Assertio's higher possible upside, research analysts clearly believe Assertio is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Do institutionals and insiders believe in ASRT or CDTX? 49.0% of Assertio shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 4.0% of Assertio shares are held by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is ASRT or CDTX more profitable? Assertio has a net margin of -54.46% compared to Cidara Therapeutics' net margin of -289.05%. Assertio's return on equity of 3.79% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Assertio-54.46% 3.79% 1.81% Cidara Therapeutics -289.05%-69.64%-33.73% Does the media prefer ASRT or CDTX? In the previous week, Cidara Therapeutics had 3 more articles in the media than Assertio. MarketBeat recorded 6 mentions for Cidara Therapeutics and 3 mentions for Assertio. Assertio's average media sentiment score of 0.89 beat Cidara Therapeutics' score of 0.88 indicating that Assertio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cidara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCidara Therapeutics beats Assertio on 11 of the 19 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.21M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.897.4422.4818.48Price / Sales0.50242.70394.56103.59Price / Cash1.1265.8538.1834.62Price / Book0.446.516.774.25Net Income-$331.94M$143.21M$3.22B$248.23M7 Day Performance3.13%1.98%1.48%0.89%1 Month Performance-1.69%6.89%3.99%3.53%1 Year Performance-29.48%-2.52%16.15%5.08% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio1.8999 of 5 stars$0.65-1.5%$2.75+323.3%-26.6%$62.21M$124.96M-0.8920Upcoming EarningsNews CoverageCDTXCidara Therapeutics4.3406 of 5 stars$20.69+6.4%$39.14+89.2%+74.4%$226.62M$1.28M-0.8190Analyst ForecastNews CoveragePositive NewsHUMAHumacyte2.7972 of 5 stars$1.45-13.7%$13.71+845.8%-63.0%$224.92M$1.57M-1.08150News CoveragePositive NewsGap DownDRUGBright Minds Biosciences3.326 of 5 stars$31.89-3.7%$84.33+164.5%+2,970.0%$224.63MN/A-187.58N/ANews CoveragePositive NewsGap DownLFCRLifecore Biomedical1.6405 of 5 stars$6.04-5.8%$8.00+32.5%+5.3%$223.63M$130.86M-10.79690ALMSAlumis2.5449 of 5 stars$4.70-6.0%$26.00+453.2%N/A$221.94MN/A0.00N/AAnalyst ForecastGap DownIMMPImmutep1.8004 of 5 stars$1.51-1.9%$8.50+462.9%-36.4%$220.52M$5.14M0.002,021CRVSCorvus Pharmaceuticals2.344 of 5 stars$3.22-0.6%$15.67+386.5%+131.6%$219.40MN/A-3.4630Upcoming EarningsNews CoverageHigh Trading VolumeYMABY-mAbs Therapeutics3.7905 of 5 stars$4.82+2.8%$18.30+279.7%-72.1%$217.95M$87.69M-8.93150Upcoming EarningsShort Interest ↓News CoverageFHTXFoghorn Therapeutics2.2579 of 5 stars$3.90+2.6%$13.17+237.6%-23.1%$216.89M$22.60M-2.03120Upcoming EarningsAnalyst ForecastNews CoverageGap DownPROKProKidney2.4919 of 5 stars$0.73-7.3%$5.00+582.2%-57.1%$214.52M$76,000.00-1.333Positive News Related Companies and Tools Related Companies Cidara Therapeutics Competitors Humacyte Competitors Bright Minds Biosciences Competitors Lifecore Biomedical Competitors Alumis Competitors Immutep Competitors Corvus Pharmaceuticals Competitors Y-mAbs Therapeutics Competitors Foghorn Therapeutics Competitors ProKidney Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASRT Stock Free ASRT Stock Alerts